Laurence Reid
Director/Board Member bei The Possible Project, Inc.
Profil
Laurence E.
Reid is currently a Director at The Possible Project, Inc. and Garuda Therapeutics, Inc. He previously served as President, Chief Executive Officer & Director at Warp Drive Bio, Inc. and Decibel Therapeutics, Inc. He was also the VP-Business Development & Strategic Planning at Millennium Pharmaceuticals, Inc. and the Chief Business Officer at Ensemble Therapeutics Corp.
Additionally, he served as the General Manager at Millennium UK Ltd and as the Chief Business Officer & Senior Vice President at Alnylam Pharmaceuticals, Inc. Dr. Reid received his undergraduate degree from the University of Cambridge and his doctorate from King's College London.
Aktive Positionen von Laurence Reid
| Unternehmen | Position | Beginn |
|---|---|---|
| The Possible Project, Inc. | Director/Board Member | - |
Garuda Therapeutics, Inc.
 Garuda Therapeutics, Inc. BiotechnologyHealth Technology Garuda Therapeutics, Inc. aims to eliminate the need for donor or patient cells for blood stem cell transplants. The company is based in Natick, MA. The company's platform technology generates off-the-shelf, self-renewing blood stem cells that are HLA-compatible and transgene-free. This technology could potentially provide curative therapies for over 120 diseases. Garuda Therapeutics was founded by Dhvanit Shah, Sean Morrison, and David T. Scadden, with Dhvanit Shah serving as CEO since incorporation. | Director/Board Member | 05.01.2022 |
Ehemalige bekannte Positionen von Laurence Reid
| Unternehmen | Position | Ende |
|---|---|---|
| DECIBEL THERAPEUTICS, INC. | Chief Executive Officer | 22.09.2023 |
Warp Drive Bio, Inc.
 Warp Drive Bio, Inc. Miscellaneous Commercial ServicesCommercial Services Warp Drive Bio, Inc. focused on proprietary genomic technology to discover drugs of natural origin. The firm deployed proprietary platforms Genome Mining and Small Molecule Assisted Receptor Targeting (SMART) to discover and develop novel molecules addressing new pharmacologic mechanisms. The company was founded by Gregory L. Verdine, George McDonald Church, and James A. Wells in 2012 and was headquartered in Cambridge, MA. | Chief Executive Officer | 01.10.2018 |
| ALNYLAM PHARMACEUTICALS, INC. | Corporate Officer/Principal | 31.12.2014 |
Millennium Pharmaceuticals, Inc.
 Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Millennium Pharmaceuticals, Inc. operates as a biopharmaceutical company. Its products include Ninlaro and Velcade. The company was founded in 1993 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | - |
Millennium UK Ltd
 Millennium UK Ltd Miscellaneous Commercial ServicesCommercial Services Part of Open Text Corp., Millennium UK Ltd is a consulting services company. The private company is based in Bournemouth, UK. Millennium was acquired by Micro Focus Group Plc on March 01, 1997 for $6.50 million. | Corporate Officer/Principal | - |
Ausbildung von Laurence Reid
| University of Cambridge | Undergraduate Degree |
| King's College London | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| ALNYLAM PHARMACEUTICALS, INC. | Health Technology |
| DECIBEL THERAPEUTICS, INC. | Health Technology |
| Private Unternehmen | 6 |
|---|---|
Millennium Pharmaceuticals, Inc.
Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Millennium Pharmaceuticals, Inc. operates as a biopharmaceutical company. Its products include Ninlaro and Velcade. The company was founded in 1993 and is headquartered in Cambridge, MA. | Health Technology |
Ensemble Therapeutics Corp.
 Ensemble Therapeutics Corp. Chemicals: Major DiversifiedProcess Industries Ensemble Therapeutics Corp. develops novel classes of therapeutics and bioassays for research and diagnostics. The firm focuses on the discovery and development of breakthrough small molecule therapies for patients with cancer and other serious diseases. The company was founded by Douglas G. Cole, Noubar B. Afeyan and David R. Liu in 2004 and is headquartered in Cambridge, MA. | Process Industries |
Millennium UK Ltd
Millennium UK Ltd Miscellaneous Commercial ServicesCommercial Services Part of Open Text Corp., Millennium UK Ltd is a consulting services company. The private company is based in Bournemouth, UK. Millennium was acquired by Micro Focus Group Plc on March 01, 1997 for $6.50 million. | Commercial Services |
Warp Drive Bio, Inc.
Warp Drive Bio, Inc. Miscellaneous Commercial ServicesCommercial Services Warp Drive Bio, Inc. focused on proprietary genomic technology to discover drugs of natural origin. The firm deployed proprietary platforms Genome Mining and Small Molecule Assisted Receptor Targeting (SMART) to discover and develop novel molecules addressing new pharmacologic mechanisms. The company was founded by Gregory L. Verdine, George McDonald Church, and James A. Wells in 2012 and was headquartered in Cambridge, MA. | Commercial Services |
| The Possible Project, Inc. | |
Garuda Therapeutics, Inc.
Garuda Therapeutics, Inc. BiotechnologyHealth Technology Garuda Therapeutics, Inc. aims to eliminate the need for donor or patient cells for blood stem cell transplants. The company is based in Natick, MA. The company's platform technology generates off-the-shelf, self-renewing blood stem cells that are HLA-compatible and transgene-free. This technology could potentially provide curative therapies for over 120 diseases. Garuda Therapeutics was founded by Dhvanit Shah, Sean Morrison, and David T. Scadden, with Dhvanit Shah serving as CEO since incorporation. | Health Technology |
